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Background
Trial evidence suggests Cladribine, a purine analogue licensed for treatment of people with hairy cell leukaemia, is also an effective, safe and convenient disease modifying therapy (DMT) for people with multiple sclerosis (pwMS)1-4. Cladribine appears to exert its effect through selective long-term suppression of lymphocytes and reduction of pro-inflammatory cytokines and chemokines whilst leaving other cell types relatively unaffected. 
Objective
To report our clinical experience with Cladribine in pwMS using a dosing scheme that adapts to individual lymphocyte level.
Methods
Cladribine was offered to pwMS with clinical and/or MRI disease activity, but restricted choice of DMT. Treatment consisted of 1-2 annual cycles of subcutaneous Cladribine (Litak). During each cycle 10mg Cladribine was given for up to 7 days in 5 weeks. The number of injections was adjusted to individual lymphocyte count to avoid levels below 0.5x10*9/L. One way ANOVA was used to analyse differences in white cell counts. We report results after a mean follow-up of 4 months.
Results
Eighteen pwMS (10 women and 8 men) had a first treatment cycle of Cladribine. Mean age was 44 (34-60) years, median EDSS was 5 (2-8). No acute side effects or serious treatment-related adverse event were observed, and neither any clinical disease activity within the follow-up period. Lymphocyte counts dropped from a mean of 1.81 (range: 0.9-3.4 x10*9) at baseline to 1.41 (0.7-3) at 4 weeks, and to 1.02 (0.6-1.6) at 8 weeks, p=0.02. Other white cells remained within normal range.
Conclusion 
Cladribine was well tolerated and led to a controlled decrease in lymphocyte counts leaving other cell lines largely unaffected. So far no new disease activity has been detected. Follow-up continues.
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